Reduction of Adverse Events of Anticholinergic Drugs by Multidisciplinary Medical Reviews in Norwegian Nursing Homes (PRADA)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
South-Eastern Norway Regional Health Authority
Norwegian Directorate of Health
Societas Pharmaciae Norvegica
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00854438
First received: February 23, 2009
Last updated: March 7, 2011
Last verified: March 2011

February 23, 2009
March 7, 2011
September 2008
September 2009   (final data collection date for primary outcome measure)
CERADS word list measuring immediately and delayed recall [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00854438 on ClinicalTrials.gov Archive Site
  • Mouth dryness [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • ADL [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Serum anticholinergic activity [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • CERADS word list recognition [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • MMSE [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • NPI [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Reduction of Adverse Events of Anticholinergic Drugs by Multidisciplinary Medical Reviews in Norwegian Nursing Homes
Pharmacist-initiated Reduction of Anticholinergic Drug Activity

Thesis: Is drug-induced anticholinergic activity additive resulting in a total anticholinergic load causing harmful side effects in old, fragile patients? Is it possible to reduce the anticholinergic load by multidisciplinary medical review including a pharmacist and a physician? The effects of the medical reviews are measured by cognitive tests (MMS and CERADS word lists), a measure of mouth dryness, serum levels of anticholinergic activity, activity of daily living and neuropsychiatric symptoms.

Design: A randomized, controlled, single blinded interventional study in Norwegian nursing homes.

Several studies have claimed that drugs showing anticholinergic activity in vitro cause high levels of serum anticholinergic activity in vivo that might cause impaired cognitive and functional functions in elderly. Pathophysiological changes in Alzheimer`s dementia makes these patients particularly vulnerable for anticholinergic cognitive impairments. The PRADA-study is the first interventional study evaluating the clinical effects of reducing drug-induced anticholinergic load in patients with dementia. This is also the first interventional study in the Nordic countries evaluating the clinical effects of clinical pharmacy.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Anticholinergic Side Effects
Other: Multidisciplinary drug reviews by pharmacist and physician
Reduction of anticholinergic drug effects by pharmacist review
  • Experimental: Active treatment arm
    Reduction of anticholinergic drug effects by pharmacist review
    Intervention: Other: Multidisciplinary drug reviews by pharmacist and physician
  • No Intervention: Control
    No intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
100
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Long-term nursing home patients with none, mild or moderate dementia (evaluated by CDR9,using drugs with a total anticholinergic burden that might lead to adverse events.

Exclusion Criteria:

  • Not able to perform the testes because of physical or psychiatric illnesses.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00854438
1110
No
Prof. Torgeir Bruun Wyller, Ullevaal University Hospital, dep of geriatric medicine
Ullevaal University Hospital
  • South-Eastern Norway Regional Health Authority
  • Norwegian Directorate of Health
  • Societas Pharmaciae Norvegica
Study Director: Torgeir B. Wyller, Professor Ullevaal University Hospital
Principal Investigator: Hege Kersten, MScPharm/PhD Ullevaal University Hospital
Oslo University Hospital
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP